VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2023 | Adaptive image guided radiotherapy for muscle invasive bladder cancer

Robert Huddart, PhD, FRCR, MRCP, MBBS, The Royal Marsden Hospital and The Institute of Cancer Research, London, UK, explains the challenges of using radiotherapy (RT) for bladder cancer treatment and discusses how adaptive RT could be a potential solution to these challenges. Prof. Huddart talks on the RAIDER trial, a randomized Phase II trial investigating adaptive tumor focused RT for patients with bladder cancer. The trial involved centers from the UK, Australia, and New Zealand, and had three arms. Patients were randomized to receive either standard whole-bladder RT, tumor boost treatment with a standard dose of RT, or tumor boost treatment with dose escalation. Patients were also divided into two cohorts, based on RT fractionation. The primary endpoint of the study aimed to assess whether dose escalation could be carried out without excess toxicity. Results have reported that the primary endpoint was met. The results also showed good local disease control, with local disease-free survival (DFS) at 2 years being 79% among the patients receiving whole bladder or non-dose-escalating treatment, and 85% among patients receiving dose-escalation. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter